Autopsy report · NCT00982657
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Cause of deathNo reason given
“Refer to statement in Summary Section/Detailed Description”
Life of this trial
- Ran for about 4 years 6 months before it stopped.
- 34 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Solid Tumor
- Interventions
- CVX-060 + sunitinib; CVX-060 + sunitinib; CVX-060 + sunitinib; CVX-060 + sunitinib; CVX-060 + sunitinib; Sunitinib
- Participants
- 34
- Sites
- 7
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.